David Nanus

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi request reprint Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen
    David M Nanus
    Department of Medicine, Joan and Stanford I Weill Medical College of Cornell University, New York, NY 10021, USA
    J Urol 170:S84-8; discussion S88-9. 2003
  2. ncbi request reprint Interaction of retinoic acid and interferon in renal cancer cell lines
    D M Nanus
    Department of Urology, Joan and Sanford I Weill Medical College of Cornell University, New York, NY 10021, USA
    J Interferon Cytokine Res 20:787-94. 2000
  3. ncbi request reprint Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma
    David M Nanus
    Department of Medicine, Weill Medical College of Cornell University, New York, New York, USA
    Cancer 101:1545-51. 2004
  4. ncbi request reprint Advanced renal cell carcinoma
    M I Milowsky
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, 525 East 68th Street, B-1519, New York, NY 10021, USA
    Curr Treat Options Oncol 2:437-45. 2001
  5. ncbi request reprint Reduced levels of retinyl esters and vitamin A in human renal cancers
    X Guo
    Department of Pharmacology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer Res 61:2774-81. 2001
  6. ncbi request reprint New treatment approaches for metastatic renal cell carcinoma
    D M Nanus
    Division of Hematology and Medical Oncology, Departments of Medicine and Urology, Joan and Sanford I Weill Medical College of Cornell University, 525 East 68th Street, B 1519, New York, NY 10021, USA
    Curr Oncol Rep 2:417-22. 2000
  7. ncbi request reprint Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein
    D M Nanus
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021
    Cancer Res 50:4190-4. 1990
  8. pmc Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment
    Trisha S Tavares
    Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA
    Cancer Biol Ther 7:1607-18. 2008
  9. pmc Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A
    D M Nanus
    Laboratory of Mammalian Cell Transformation, Memorial Sloan Kettering Cancer Center, New York, NY 10021
    Proc Natl Acad Sci U S A 90:7069-73. 1993
  10. ncbi request reprint Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach
    Ashutosh Tewari
    Brady Urologic Health Center, New York Presbyterian Hospital and Robotic Prostatectomy and Urologic Oncology Outcomes, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Urol 177:911-5. 2007

Collaborators

Detail Information

Publications56

  1. ncbi request reprint Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen
    David M Nanus
    Department of Medicine, Joan and Stanford I Weill Medical College of Cornell University, New York, NY 10021, USA
    J Urol 170:S84-8; discussion S88-9. 2003
    ..Monoclonal antibody (mAb) J591 recognizes the extracellular domain of PSMA. The current status of clinical trials using mAb J591 is reviewed...
  2. ncbi request reprint Interaction of retinoic acid and interferon in renal cancer cell lines
    D M Nanus
    Department of Urology, Joan and Sanford I Weill Medical College of Cornell University, New York, NY 10021, USA
    J Interferon Cytokine Res 20:787-94. 2000
    ..IFN-gamma pretreatment enhanced the upregulation of p48 levels by IFN-alpha. Combining RA and IFN results in additive growth inhibition on RCC cell lines. This increase in growth inhibition is not mediated by increased ISGF3 expression...
  3. ncbi request reprint Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma
    David M Nanus
    Department of Medicine, Weill Medical College of Cornell University, New York, New York, USA
    Cancer 101:1545-51. 2004
    ..Based on the antitumor activity of doxorubicin and gemcitabine in collecting duct carcinoma of the kidney, the authors used this combination to treat selected patients with sarcomatoid or rapidly progressing RCC...
  4. ncbi request reprint Advanced renal cell carcinoma
    M I Milowsky
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, 525 East 68th Street, B-1519, New York, NY 10021, USA
    Curr Treat Options Oncol 2:437-45. 2001
    ..The identification of new agents with more effective antitumor activity is a high priority in the treatment of advanced RCC...
  5. ncbi request reprint Reduced levels of retinyl esters and vitamin A in human renal cancers
    X Guo
    Department of Pharmacology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer Res 61:2774-81. 2001
    ....
  6. ncbi request reprint New treatment approaches for metastatic renal cell carcinoma
    D M Nanus
    Division of Hematology and Medical Oncology, Departments of Medicine and Urology, Joan and Sanford I Weill Medical College of Cornell University, 525 East 68th Street, B 1519, New York, NY 10021, USA
    Curr Oncol Rep 2:417-22. 2000
    ..A number of novel treatment strategies are being investigated with some encouraging early results. The identification of new agents with better antitumor activity remains a high priority in the treatment of advanced renal cell carcinoma...
  7. ncbi request reprint Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein
    D M Nanus
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021
    Cancer Res 50:4190-4. 1990
    ..We conclude that the absence of gp160 expression by RCs may be predictive of sensitivity to the antitumor effects of IFN-alpha and, thus, provide a basis for identifying IFN-responsive patients...
  8. pmc Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment
    Trisha S Tavares
    Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA
    Cancer Biol Ther 7:1607-18. 2008
    ..Together, our results show that treatment of RCC with cRA and/or SAHA increases the expression of several genes and gene families that result in reduced cell proliferation...
  9. pmc Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A
    D M Nanus
    Laboratory of Mammalian Cell Transformation, Memorial Sloan Kettering Cancer Center, New York, NY 10021
    Proc Natl Acad Sci U S A 90:7069-73. 1993
    ..These data indicate that the gp160 human kidney/RCC glycoprotein is human APA...
  10. ncbi request reprint Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach
    Ashutosh Tewari
    Brady Urologic Health Center, New York Presbyterian Hospital and Robotic Prostatectomy and Urologic Oncology Outcomes, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Urol 177:911-5. 2007
    ....
  11. ncbi request reprint Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells
    J Dai
    Department of Urology, Urological Oncology Research Laboratory, Joan and Stanford I. Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 7:1370-7. 2001
    ..These data show that NEP can inhibit PC cell growth and tumorigenicity and suggest that NEP has potential as therapy for androgen-independent PC...
  12. ncbi request reprint Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway
    M Sumitomo
    Urologic Oncology Research Laboratory, Department of Urology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Res 61:3294-8. 2001
    ..These data show that the neuropeptides ET-1 and bombesin stimulate ligand-independent activation of the IGF-IR, which results in Akt activation, and that this cross-communication between GPCR and IGF-IR signaling is inhibited by NEP...
  13. pmc Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling
    M Sumitomo
    Urologic Oncology Research Laboratory, Department of Urology, and Department of Pathology, Weill Medical College of Cornell University, New York, New York, USA
    J Clin Invest 106:1399-407. 2000
    ....
  14. pmc Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer
    B A Usmani
    Genitourinary Oncology Research Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Br J Cancer 82:550-2. 2000
    ..The observed frequencies in patients who develop renal cancer was not significantly different than the normal population...
  15. ncbi request reprint Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma
    Stephen A Boorjian
    Department of Urology, the Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Immunother 30:655-62. 2007
    ..The addition of weekly ATRA-IV to IFN therapy is feasible and well tolerated, resulting in sustainable increased serum (RA). This regimen demonstrates antitumor activity in metastatic RCC, and suggests ATRA-IV augments IFN therapy...
  16. ncbi request reprint Neutral endopeptidase protein expression and prognosis in localized prostate cancer
    Iman Osman
    Department of Urology, New York University Cancer Institute, Kaplan Comprehensive Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4096-100. 2004
    ..We investigated whether decreased NEP expression in localized prostate cancers is associated with prostate-specific antigen (PSA) relapse after radical prostatectomy...
  17. ncbi request reprint Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Shankar Vallabhajosula
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, New York, USA
    J Nucl Med 46:634-41. 2005
    ..The radiation dosimetry of 90Y-J591 was estimated based on both 111In and 177Lu data to validate the usage of 111In as a chemical and biologic surrogate for 90Y...
  18. ncbi request reprint Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
    Neil H Bander
    Department of Urology, Weill Medical College of Cornell University, 525 E 68th St, E 300, New York, NY 10021, USA
    J Clin Oncol 23:4591-601. 2005
    ....
  19. ncbi request reprint Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model
    Sue Ellen Touma
    Department of Pharmacology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 11:3558-66. 2005
    ..Therefore, we tested whether combining histone deacetylase inhibitors with retinoic acid (RA) would restore RARbeta2 receptor expression, leading to increased growth inhibition in RCC cells...
  20. ncbi request reprint Involvement of neutral endopeptidase in neoplastic progression
    Makoto Sumitomo
    Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359 8513, Japan
    Biochim Biophys Acta 1751:52-9. 2005
    ..We review the mechanisms of NEP's tumor suppressive action and how NEP loss contributes to tumor progression...
  21. ncbi request reprint Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity
    Shankar Vallabhajosula
    Department of Radiology, Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York 10021, USA
    Clin Cancer Res 11:7195s-7200s. 2005
    ..Fractionated dose regimens may decrease myelotoxicity and increase greater total administered dose. We have studied the effect of two or three treatments of 177Lu-J591 and 90Y-J591 monoclonal antibodies (mAb) on myelotoxicity...
  22. ncbi request reprint Clinical utility of radiolabeled monoclonal antibodies in prostate cancer
    Kevin A David
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Genitourin Cancer 4:249-56. 2006
    ..Additional studies are under way to better define the activity of radiolabeled antibody therapy as well as the role for fractionated therapy and combination approaches with taxane-based chemotherapy...
  23. ncbi request reprint Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2
    Oscar B Goodman
    Urologic Oncology Research Laboratory, Department of Urology, Weil Medical College of Cornell University New York Presbyterian Hospital, New York, NY 10021, USA
    J Biol Chem 281:33597-605. 2006
    ..These data indicate that neprilysin proteolytically inactivates fibroblast growth factor-2, resulting in negative regulation of angiogenesis...
  24. ncbi request reprint Chemotherapy for non-clear-cell renal cell carcinoma
    Kevin A David
    Department of Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, NY 10021, USA
    Clin Genitourin Cancer 4:263-8. 2006
    ..In this article, we will review the literature and present our experience with the use of chemotherapy in patients with non-clear-cell kidney cancer by histologic subtype...
  25. ncbi request reprint Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression
    Iman Osman
    Department of Urology, New York University Cancer Institute, New York, New York, USA
    Cancer 107:2628-36. 2006
    ....
  26. ncbi request reprint Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors
    Matthew I Milowsky
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York 10021, USA
    J Clin Oncol 25:540-7. 2007
    ..This was a proof-of-principle evaluation of PSMA as a potential neovascular target. The primary end points were targeting,toxicity, maximum-tolerated dose, pharmacokinetics (PK), and human antihuman antibody (HAHA) response...
  27. ncbi request reprint Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer
    Stephen Boorjian
    Department of Urology, New York Presbyterian Hospital Weill Cornell Medical Center, New York, New York 10021, USA
    Clin Cancer Res 10:3429-37. 2004
    ..Here we evaluated expression of LRAT protein and mRNA in normal and malignant bladder tissue specimens from human patients. We also examined the effect of retinoids on LRAT expression in bladder cancer cell lines...
  28. ncbi request reprint Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial
    Maha H A Hussain
    University of Michigan, Ann Arbor, USA
    J Clin Oncol 25:2218-24. 2007
    ....
  29. ncbi request reprint Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
    Matthew I Milowsky
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 22:2522-31. 2004
    ....
  30. ncbi request reprint Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature
    Matthew I Milowsky
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 94:111-6. 2002
    ..To the authors' knowledge, there are no standard treatment regimens and neither immunotherapy nor chemotherapy have been found to be effective...
  31. ncbi request reprint Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen
    Neil H Bander
    Department of Urology, Division of Nuclear Medicine, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 East 68th Street, Starr 900, New York, NY 10021, USA
    J Urol 170:1717-21. 2003
    ....
  32. ncbi request reprint Chemotherapeutic strategies for renal cell carcinoma
    Matthew I Milowsky
    Division of Hematology Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, 525 East 68th Street, ST 359, New York, NY 10021, USA
    Urol Clin North Am 30:601-9, x. 2003
    ..The identification of novel agents with significantly improved antitumor activity remains a high priority in the treatment of this disease...
  33. ncbi request reprint Detection of the p110 beta subunit of phosphatidylinositol 3-kinase complexed with neutral endopeptidase
    Ruoqian Shen
    Laboratory of Urological Oncology, Department of Urology, Joan and Sanford I Weill Medical College of Cornell University, 1300 York Avenue, E 300 Box 23, New York, NY 10021, USA
    Anticancer Res 22:2533-8. 2002
    ..We previously reported that NEP directly associated with tyrosine-phosphorylated Lyn kinase, and with the p85 subunit of the phosphatidylinositol 3-kinase (PI3 kinase) resulting in an NEP-Lyn-PI3 kinase protein complex...
  34. ncbi request reprint High expression of the Met receptor in prostate cancer metastasis to bone
    Beatrice S Knudsen
    Department ofPathology, Weill Medical College of Cornell University, New York, New York, USA
    Urology 60:1113-7. 2002
    ....
  35. ncbi request reprint Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma
    Jonathan S Goldberg
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 95:1220-7. 2002
    ..Liposome-encapsulated all-trans RA (ATRA-IV) has improved pharmacokinetics with increased and prolonged ATRA serum levels compared with oral retinoids...
  36. ncbi request reprint The utility of monoclonal antibodies in the imaging of prostate cancer
    Daniel Yao
    James Buchanan Brady Department of Urology, The New York Presbyterian Hospital Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Urol Oncol 20:211-8. 2002
    ..Radioimmunoscintigraphy with this immunoconjugate has demonstrated excellent tumor targeting of prostate cancer sites not only in soft tissue but also in bone...
  37. ncbi request reprint Estramustine plus a taxane for advanced prostate cancer: the new standard therapy?
    Matthew I Milowsky
    Cancer Invest 20:849-50. 2002
  38. ncbi request reprint Synergistic activation of the androgen receptor by bombesin and low-dose androgen
    Jie Dai
    Urologic Oncology Research Laboratory, Department of Urology, Joan and Stanford I Weill Medical College, Cornell University, New York, New York 10021, USA
    Clin Cancer Res 8:2399-405. 2002
    ..Neuropeptide growth factors such as bombesinare implicated in progression to androgen-independent prostate cancer (PC). We examined the impact of bombesin on androgen receptor (AR)-mediated gene expression...
  39. ncbi request reprint Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen
    Neil H Bander
    Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Oncol 30:667-76. 2003
    ..Imaging of patients after they have received radiolabeled J591 demonstrates excellent tumor targeting...
  40. ncbi request reprint Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen
    Shankar Vallabhajosula
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 E 68th Street, STARR 221, New York, NY 10021, USA
    J Nucl Med 46:850-8. 2005
    ....
  41. ncbi request reprint Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN
    Makoto Sumitomo
    Urological Oncology Research Laboratory, Department of Urology, Joan and Stanford I Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Cell 5:67-78. 2004
    ..This study demonstrates a molecular cooperation between NEP and PTEN tumor suppressors in which NEP constitutively recruits and activates PTEN to inhibit the PI3K/Akt oncogenic pathway...
  42. ncbi request reprint Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens
    Xiaojia Guo
    Department of Pharmacology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer Res 62:1654-61. 2002
    ..Collectively, these data implicate aberrant retinoid metabolism in the process of prostatic carcinogenesis...
  43. ncbi request reprint Antibody-based therapeutics: focus on prostate cancer
    Jeffrey S Ross
    Millennium Pharmaceuticals, Inc, Cambridge, MA, USA
    Cancer Metastasis Rev 24:521-37. 2005
    ....
  44. doi request reprint Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells
    Akio Horiguchi
    Urologic Oncology Research Laboratory, Department of Urology, Weill Cornell Medical College of Cornell University, New York, New York, USA
    Prostate 68:975-84. 2008
    ..We examined the regulation of merlin expression and merlin phosphorylation in prostate cancer cells...
  45. ncbi request reprint Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2
    Oscar B Goodman
    Urologic Oncology Research Laboratory, Department of Urology, Weill Medical College of Cornell University New York Presbyterian Hospital, New York, NY, USA
    Int J Oncol 31:1199-203. 2007
    ..Thus, although PSMA is a new member of the dual AP and clathrin binding proteins, its alpha-adaptin and clathrin heavy chain binding determinants are distinct from those of other members...
  46. ncbi request reprint Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base
    Kevin A David
    Department of Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York, USA
    J Urol 178:451-4. 2007
    ..We reviewed chemotherapy use in patients with stage III transitional cell carcinoma of the bladder from 1998 to 2003 to evaluate perioperative chemotherapy treatment patterns...
  47. pmc Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells
    Jin Zhu
    Department of Urology, Weill Medical College of Cornell University and New York Presbyterian Hospital, Rm E 300, Box 23, 1300 York Ave, New York, NY 10021, USA
    Biochim Biophys Acta 1773:1087-94. 2007
    ....
  48. ncbi request reprint Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase
    Makoto Sumitomo
    Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Clin Cancer Res 10:260-6. 2004
    ..We investigated whether neutral endopeptidase (NEP) could augment chemosensitivity to anticancer drugs by promoting protein kinase C (PKC)delta-mediated mitochondrial apoptosis in prostate cancer (PC) cells...
  49. ncbi request reprint Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins
    Akira Iwase
    Urologic Oncology Research Laboratory, Department of Urology, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Biol Chem 279:11898-905. 2004
    ..Moreover, cells expressing wild-type NEP demonstrate decreased adhesion to hyaluronic acid and cell migration. These data suggest that NEP can affect cell adhesion and migration through direct binding to ERM proteins...
  50. ncbi request reprint Of peptides and peptidases: the role of cell surface peptidases in cancer
    David M Nanus
    Clin Cancer Res 9:6307-9. 2003
  51. ncbi request reprint Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney
    Hui Chun Zhan
    Pharmacology Department, Weill Medical College, Cornell University, New York, New York 10021, USA
    Clin Cancer Res 9:4897-905. 2003
    ..This prompted us to examine the levels of LRAT (lecithin:retinol acyltransferase) protein in various subtypes of human kidney cancers relative to normal human kidney by immunohistochemistry...
  52. ncbi request reprint Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma
    Akio Horiguchi
    Department of Urology, National Defense Medical College, Tokorozawa City, Saitama, Japan
    J Urol 176:1631-5. 2006
    ..Because obesity is a significant risk factor for renal cell carcinoma, we investigated the link between leptin and the development of renal cell carcinoma...
  53. ncbi request reprint Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter
    Rong Zheng
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, 525 E 68th Street, ST 359, NY 10021, USA
    Mol Cell Endocrinol 259:10-21. 2006
    ....
  54. ncbi request reprint Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco 94115 1711, USA
    J Urol 170:S3-5. 2003
  55. ncbi request reprint Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma
    Jay D Raman
    Department of Urology, The New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA
    Carcinogenesis 27:499-507. 2006
    ..In summary, we were able to detect Rex-1 mRNA and protein expression in over 90% of normal renal parenchymal specimens and we observed a significant reduction in REX1 expression in renal tumor specimens of all histologic subtypes...
  56. ncbi request reprint Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway
    Akio Horiguchi
    Department of Urology, National Defense Medical College, Saitama, Japan
    J Urol 176:1636-41. 2006
    ..We examined whether leptin promotes the invasiveness of renal cancer cells and we investigated its underlying signaling pathway...

Research Grants14

  1. NEUTRAL ENDOPEPTIDASE INACTIVATION IN ADVANCED PROSTATE
    David Nanus; Fiscal Year: 2005
    ..abstract_text> ..
  2. ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES
    David Nanus; Fiscal Year: 2004
    ..This award will allow Dr. Nanus protected time to successfully complete these aims. ..
  3. NEUTRAL ENDOPEPTIDASE INACTIVATION IN ADVANCED PROSTATE
    David Nanus; Fiscal Year: 2001
    ..These studies leading to a better understanding of the involvement of NEP in the development and progression of androgen- independent PC may ultimately provide support for novel approaches for the treatment of advanced PC. ..
  4. Modulation of retinoic acid action in renal cancer
    David Nanus; Fiscal Year: 2005
    ....